{
  "id": 1774,
  "text": "74 $9 5 ~ \\mathrm { C I } = 0 .5 3 \\substack { - 1 .0 5 }$ , ${ \\bf p } = { \\bf \\Phi }$ 0.09).The response rates were $4 7 \\%$ and $2 7 \\% .$ , respectively $[ \\mathrm { p } = 0 .0 0 2 \\AA$ .It should be noted that as compared with cisplatin/paclitaxel (either with or without bevacizumab) topotecan/paclitaxel was associated with (1) a significantly higher risk of progression $[ \\mathrm { H R } =$ 1.",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 74 $9 5 ~ \\mathrm { C I } = 0 .5 3 \\substack { - 1 .0 5 }$ , ${ \\bf p } = { \\bf \\Phi }$ 0.09).The response rates were $4 7 \\%$ and $2 7 \\% .$ , respectively $[ \\mathrm { p } = 0 .0 0 2 \\AA$ .It should be noted that as compared with cisplatin/paclitaxel (either with or without bevacizumab) topotecan/paclitaxel was associated with (1) a significantly higher risk of progression $[ \\mathrm { H R } =$ \n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "在治疗宫颈癌的研究中，含有或不含贝伐珠单抗的顺铂/紫杉醇与拓扑替康/紫杉醇的方案相比，存在显著差异。首先，从反应率来看，顺铂/紫杉醇（不论是否合用贝伐珠单抗）的反应率为47%，而拓扑替康/紫杉醇的反应率较低，为27%。这表明顺铂/紫杉醇方案可能在整体反应率上更为有效。其次，在疾病进展的风险方面，拓扑替康/紫杉醇的治疗方案与顺铂/紫杉醇相比，存在更高的进展风险。这提示顺铂/紫杉醇在控制病情进展方面可能表现更优。因此，在选择治疗方案时，这些数据可以提供一定的指导依据。",
  "query": "如果有比较含有或不含贝伐珠单抗的顺铂/紫杉醇与拓扑替康/紫杉醇的不同反应率和进展风险的研究结果，它们在治疗效果上有何差异？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 如果有比较含有或不含贝伐珠单抗的顺铂/紫杉醇与拓扑替康/紫杉醇的不同反应率和进展风险的研究结果，它们在治疗效果上有何差异？\n\n<reference text>: 74 $9 5 ~ \\mathrm { C I } = 0 .5 3 \\substack { - 1 .0 5 }$ , ${ \\bf p } = { \\bf \\Phi }$ 0.09).The response rates were $4 7 \\%$ and $2 7 \\% .$ , respectively $[ \\mathrm { p } = 0 .0 0 2 \\AA$ .It should be noted that as compared with cisplatin/paclitaxel (either with or without bevacizumab) topotecan/paclitaxel was associated with (1) a significantly higher risk of progression $[ \\mathrm { H R } =$ 1.\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "在治疗宫颈癌的研究中，含有或不含贝伐珠单抗的顺铂/紫杉醇与拓扑替康/紫杉醇的方案相比，存在显著差异。首先，从反应率来看，顺铂/紫杉醇（不论是否合用贝伐珠单抗）的反应率为47%，而拓扑替康/紫杉醇的反应率较低，为27%。这表明顺铂/紫杉醇方案可能在整体反应率上更为有效。其次，在疾病进展的风险方面，拓扑替康/紫杉醇的治疗方案与顺铂/紫杉醇相比，存在更高的进展风险。这提示顺铂/紫杉醇在控制病情进展方面可能表现更优。因此，在选择治疗方案时，这些数据可以提供一定的指导依据。"
}